Genistein suppresses allergic contact dermatitis through regulating the MAP2K2/ERK pathway

Area of Science:

• Dermatology
• Immunology
• Molecular Biology

Background:

• Genistein, a soy isoflavone, shows promise for various diseases.
• Its therapeutic role in chronic skin conditions is emerging, but mechanisms are unclear.
• Allergic contact dermatitis (ACD) is a prevalent inflammatory skin condition.

Purpose of the Study:

• To investigate genistein's efficacy in mitigating squaric acid dibutylester (SADBE)-induced ACD in mice.
• To elucidate the molecular mechanisms underlying genistein's effects on ACD.
• To assess genistein's impact on inflammatory markers and signaling pathways.

Main Methods:

• SADBE-induced ACD model in mice.
• Assessment of pro-inflammatory cytokines (CXCL9, TSLP, TNF-α, IL-1β, IL-6) in skin and serum.
• Analysis of MAPK and JAK-STAT3 pathway phosphorylation in skin and dorsal root ganglions (DRGs).
• In vitro studies using TNF-α/IFN-γ-stimulated HaCaT cells and siRNA knockdown of MAP2K2/MAP2K4.

Main Results:

• Genistein significantly reduced skin damage and inflammatory cell infiltration in ACD mice.
• Genistein suppressed elevated pro-inflammatory factors in skin and blood.
• Genistein downregulated phosphorylation of ERK, p38, and STAT3 in skin and DRGs.
• Genistein inhibited ERK and STAT3 phosphorylation in HaCaT cells, reducing cytokine/chemokine expression and feedback inhibiting p38 phosphorylation.
• MAP2K2 knockdown reversed genistein's inhibitory effect on the MAPK pathway.

Conclusions:

• Genistein demonstrates potent antipruritic and anti-inflammatory effects in ACD.
• Genistein acts by inhibiting pro-inflammatory cytokine production.
• Genistein targets the MAP2K2/ERK signaling pathway, offering a potential therapeutic strategy for contact dermatitis and related conditions.